Other news to note for March 17, 2020

Biopharma happenings in Asia-Pacific, such as deals and partnerships, grants, preclinical data and other news in brief, including: Abcellera, Airway, Arctic Vision Shanghai, Athenex, Aytu, Biogen, Brii, Chembio Diagnostics, Clearside, Context, Correvio, Cytovance, Eli Lilly, Emergent Biosolutions, GT Biopharma, Hitgen, Hong Kong Teson, I-Mab, Immunoprecise Antibodies, Innovation, Kaken, Kamada, Kirin, La Jolla, Lattice, Lumiradx, Mallinckrodt, Medicago, Mesoblast, Nanoviricides, Nicox, Novavax, Ocumension, Olix, Oncosec, Pharmamar, Pluristem, Protalix, Qiagen, Roche, Sengenics, TFF, Tiziana Life Sciences, Twist, Tyligand, Vir, Xavier Saelens, Xortx, Zhejiang Orient Gene Biotech.

Financings for March 17, 2020

Biopharmas in Asia-Pacific raising money in public or private financings, including: Biocure Pharm, Bristol Myers Squibb, Harbour Biomed, Life Sciences Partners, Otsuka, Quest Pharmatech, Tiziana Life Sciences.

Regulatory front for March 17, 2020

The latest global regulatory news, changes and updates affecting biopharma, including: U.S. Trade Representative, World Trade Organization.

Clinical data for March 10-16, 2020

Clinical updates from Asia, including trial initiations, enrollment status and data readouts and publications, including: Moderna, Regeneron, Sanofi, Santen, Takeda, Tracon.

Regulatory actions for March 10-16, 2020

Regulatory snapshots, including drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations in Asia-Pacific, including: Cytodyn, Zai Lab.